Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12947MR)

This product GTTS-WQ12947MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF12A gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51330
UniProt ID Q9NP84
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12947MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13268MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ937MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ6118MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ3415MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ2359MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ8589MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ9892MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ9782MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW